ERBB2 and breast cancer: Another randomized phase 3 trial in metastatic HER2 positive breast cancer patients also showed that addition of bevacizumab to trastuzumab and chemotherapy did not increase PFS (11.1 months without versus 12.2 months with bevacizumab; HR 0.65, P = .10) [49].